<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>intensive care and critical care medicine</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>intensive care and critical care medicine | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Effect of Heparin and Tocilizumab in Patients with Severe COVID-19: The HEPMAB Randomized Clinical Trial
Authors: Ribeiro, L.; Landoni, G.; Quintao, V. C.; de Lacerda, M. V. G.; Rizk, S. I.; da Silva Costa, I. B. S.; de Almeida Andrade, F. T.; Melo, E. d. S.; dos Santos Neto, N. C.; de Gonzalez, T. B.; Ferreira Reis, L. B.; de Freitas Costa, V.; Machado, T. I. V.; da Costa Ribeiro, S.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/intensive-care-and-critical-care-medicine/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="intensive care and critical care medicine" />
<meta property="og:description" content="Effect of Heparin and Tocilizumab in Patients with Severe COVID-19: The HEPMAB Randomized Clinical Trial
Authors: Ribeiro, L.; Landoni, G.; Quintao, V. C.; de Lacerda, M. V. G.; Rizk, S. I.; da Silva Costa, I. B. S.; de Almeida Andrade, F. T.; Melo, E. d. S.; dos Santos Neto, N. C.; de Gonzalez, T. B.; Ferreira Reis, L. B.; de Freitas Costa, V.; Machado, T. I. V.; da Costa Ribeiro, S." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/intensive-care-and-critical-care-medicine/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-12-31T10:38:19+00:00" />
<meta property="article:modified_time" content="2023-12-31T10:38:19+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="intensive care and critical care medicine"/>
<meta name="twitter:description" content="Effect of Heparin and Tocilizumab in Patients with Severe COVID-19: The HEPMAB Randomized Clinical Trial
Authors: Ribeiro, L.; Landoni, G.; Quintao, V. C.; de Lacerda, M. V. G.; Rizk, S. I.; da Silva Costa, I. B. S.; de Almeida Andrade, F. T.; Melo, E. d. S.; dos Santos Neto, N. C.; de Gonzalez, T. B.; Ferreira Reis, L. B.; de Freitas Costa, V.; Machado, T. I. V.; da Costa Ribeiro, S."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "intensive care and critical care medicine",
      "item": "https://trxiv.yorks0n.com/posts/intensive-care-and-critical-care-medicine/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "intensive care and critical care medicine",
  "name": "intensive care and critical care medicine",
  "description": "Effect of Heparin and Tocilizumab in Patients with Severe COVID-19: The HEPMAB Randomized Clinical Trial\nAuthors: Ribeiro, L.; Landoni, G.; Quintao, V. C.; de Lacerda, M. V. G.; Rizk, S. I.; da Silva Costa, I. B. S.; de Almeida Andrade, F. T.; Melo, E. d. S.; dos Santos Neto, N. C.; de Gonzalez, T. B.; Ferreira Reis, L. B.; de Freitas Costa, V.; Machado, T. I. V.; da Costa Ribeiro, S.",
  "keywords": [
    
  ],
  "articleBody": " Effect of Heparin and Tocilizumab in Patients with Severe COVID-19: The HEPMAB Randomized Clinical Trial\nAuthors: Ribeiro, L.; Landoni, G.; Quintao, V. C.; de Lacerda, M. V. G.; Rizk, S. I.; da Silva Costa, I. B. S.; de Almeida Andrade, F. T.; Melo, E. d. S.; dos Santos Neto, N. C.; de Gonzalez, T. B.; Ferreira Reis, L. B.; de Freitas Costa, V.; Machado, T. I. V.; da Costa Ribeiro, S. C.; Vieira, A. P. Z.; Huemer, N.; Silva, F.; Park, C. L.; Fukushima, J. T.; Guimaraes Junior, M. H.; Cota, M. d. A. L.; Kawahara, L. T.; Sakaguchi Barros, C. C.; Muller, A.; Nakada, L.; de Paiva Pinto, B. F.; Bergamin, F. S.; Santos, E. S.; dos Santos Figueira, F. A. M.; de Paula, L. J. C.; Filho, R. K.; Hajjar, L.\nScore: 5.8, Published: 2023-12-27 DOI: 10.1101/2023.12.22.23300466\nBackgroundClinical presentation of severe Coronavirus disease 2019 (COVID-19) is associated to an intense inflammatory response and thrombogenesis. The benefits of the association of interleukin-6 receptor blockade (tocilizumab) and therapeutic-dose anticoagulation remains unclear. We aimed to assess whether heparin and tocilizumab could effectively reduce inflammation and thrombogenesis in severe COVID-19 patients. MethodsThis is an open-label, multicenter, randomized, clinical trial, involving patients with severe COVID-19 infection. Eligible patients were randomly assigned in a 1:1:1:1 ratio to receive either therapeutic or prophylactic anticoagulation with heparin, with or without an intravenous single dose of tocilizumab. The participants in the study were assigned to one of the four distinct arms: 1) therapeutic anticoagulation; 2) prophylactic anticoagulation; 3) therapeutic anticoagulation plus a single intravenous dose of tocilizumab; and 4) prophylactic anticoagulation plus a single intravenous dose of tocilizumab. The primary outcome was clinical improvement at day 30, defined as a composite of hospital discharge and/or a reduction of at least 2 points of the modified ordinal scale of 7 points recommended by the World Health Organization. ResultsWe enrolled 308 patients. Patients randomized to receive therapeutic anticoagulation more frequently had clinical improvement at day 30 when compared to the prophylactic anticoagulation patients [64/75 (85%) versus 51/80 (64%), odds ratio, 3.31; 95% confidence interval, 1.51; 7.26 P=0.003]. Major bleeding was more frequent in the therapeutic anticoagulation group (6.7%) and in the therapeutic anticoagulation plus tocilizumab group (5.0%), compared to the prophylactic anticoagulation group (P=0.02). All-cause mortality at day 30 was significantly lower in therapeutic anticoagulation group (9.3%), when compared to prophylactic anticoagulation group (28.7%), therapeutic anticoagulation plus tocilizumab group (21.5%) and prophylactic anticoagulation plus tocilizumab group (25.7%), P=0.02. ConclusionsIn this randomized clinical trial involving severe COVID-19 patients, therapeutic anticoagulation resulted in clinical improvement at 30 days. Even if therapeutic anticoagulation increased bleeding, it was associated with a reduced overall mortality. Tocilizumab did not provide additional benefits to heparin in COVID-19 patients. Trial registrationClinicaltrials.gov NCT04600141. Registered October 22, 2020. https://www.clinicaltrials.gov/study/NCT04600141?term=NCT04600141\u0026rank=1\nAddressing the aftermath of the COVID-19 pandemic: A quality improvement collaborative to optimize the use of antibacterials in Argentine Intensive Care Units\nAuthors: Jorro-Baron, F.; Loudet, C.; Cornistein, W.; Suarez-Anzorena, I.; Arias-Lopez, P.; Balasini, C.; Cabana, L.; Cunto, E.; Corral, R.; Gibbons, L.; Guglielmino, M.; Izzo, G.; Lescano, M.; Meregalli, C.; Orlandi, C.; Perre, F.; Ratto, M. E.; Rivet, M.; Rodriguez, A. P.; Rodriguez, V. M.; Villegas, P. R.; Vitar, E.; Roberti, J.; Garcia-Elorrio, E.; Rodriguez, V.\nScore: 0.5, Published: 2023-12-29 DOI: 10.1101/2023.12.28.23300542\nBackground: Reducing antimicrobial resistance is a global priority that become even more important after the COVID-19 pandemic. To date there is a scarce volume of evidence from antimicrobial stewardship programs from less resourced settings where this phenomenon is bigger. Our aim was to improve the quality of antibacterials prescription in intensive care units (ICUs) in a middle-income country. Methods: We established a quality improvement collaborative (QIC) model involving nine ICUs over an 11-month period, with a 16-week baseline (BP) and 32-week Intervention (IP) periods. Our co-designed intervention package included audits and feedback on antibacterial use, facility-specific treatment guidelines, antibacterial timeouts, pharmacy-based interventions, and education. The intervention was delivered in two learning sessions with three action periods, along with coaching support and basic quality improvement training. Results: We enrolled 912 patients, with 357 in baseline period (BP) and 555 in implementation period (IP). The latter had higher APACHE II (17 (12, 21) vs. 15 (11, 20); p=0.036) and SOFA scores (6 (4, 9) vs. 5 (3, 8); p=0.006), sepsis (36.1% vs. 31.6%, p\u003c0.001), and septic shock (40.0% vs. 33.8%, p\u003c0.001). Days of antibacterial therapy were similar between groups (IP 1112.2, BP 1133.4, RR 0.98 (0.95-1.02); p=0.2973) and the antibacterial Daily Define Dose was lower in IP group (IP, 1193.0; BP, 1301.0; RR, 0.92 (0.89, 0.95); p=0.0001). The rate of adequate antibacterial adjustment was higher during the IP (62.0% vs. 45.3%, p\u003c0.001). We observed a lower rate of ventilation-associated pneumonia and catheter-associated urinary tract infections related to multidrug-resistant organisms (MDRO) in the IP. There was a noticeable improvement in the Infection Prevention and Control (IPC) Assessment Framework compared to baseline. Conclusion: The implementation of a post pandemic antimicrobial stewardship program in ICUs via a QIC demonstrated success in improving antibacterials utilization, reducing HAIs related to MDRO while also enhancing IPC measures.\n",
  "wordCount" : "842",
  "inLanguage": "en",
  "datePublished": "2023-12-31T10:38:19Z",
  "dateModified": "2023-12-31T10:38:19Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/intensive-care-and-critical-care-medicine/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      intensive care and critical care medicine
    </h1>
    <div class="post-meta">&lt;span&gt;updated on December 31, 2023&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.22.23300466">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.22.23300466" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.22.23300466">
        <p class="paperTitle">Effect of Heparin and Tocilizumab in Patients with Severe COVID-19: The HEPMAB Randomized Clinical Trial</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.22.23300466" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.22.23300466" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Ribeiro, L.; Landoni, G.; Quintao, V. C.; de Lacerda, M. V. G.; Rizk, S. I.; da Silva Costa, I. B. S.; de Almeida Andrade, F. T.; Melo, E. d. S.; dos Santos Neto, N. C.; de Gonzalez, T. B.; Ferreira Reis, L. B.; de Freitas Costa, V.; Machado, T. I. V.; da Costa Ribeiro, S. C.; Vieira, A. P. Z.; Huemer, N.; Silva, F.; Park, C. L.; Fukushima, J. T.; Guimaraes Junior, M. H.; Cota, M. d. A. L.; Kawahara, L. T.; Sakaguchi Barros, C. C.; Muller, A.; Nakada, L.; de Paiva Pinto, B. F.; Bergamin, F. S.; Santos, E. S.; dos Santos Figueira, F. A. M.; de Paula, L. J. C.; Filho, R. K.; Hajjar, L.</p>
        <p class="info">Score: 5.8, Published: 2023-12-27 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.22.23300466' target='https://doi.org/10.1101/2023.12.22.23300466'> 10.1101/2023.12.22.23300466</a></p>
        <p class="abstract">BackgroundClinical presentation of severe Coronavirus disease 2019 (COVID-19) is associated to an intense inflammatory response and thrombogenesis. The benefits of the association of interleukin-6 receptor blockade (tocilizumab) and therapeutic-dose anticoagulation remains unclear. We aimed to assess whether heparin and tocilizumab could effectively reduce inflammation and thrombogenesis in severe COVID-19 patients.

MethodsThis is an open-label, multicenter, randomized, clinical trial, involving patients with severe COVID-19 infection. Eligible patients were randomly assigned in a 1:1:1:1 ratio to receive either therapeutic or prophylactic anticoagulation with heparin, with or without an intravenous single dose of tocilizumab. The participants in the study were assigned to one of the four distinct arms: 1) therapeutic anticoagulation; 2) prophylactic anticoagulation; 3) therapeutic anticoagulation plus a single intravenous dose of tocilizumab; and 4) prophylactic anticoagulation plus a single intravenous dose of tocilizumab. The primary outcome was clinical improvement at day 30, defined as a composite of hospital discharge and/or a reduction of at least 2 points of the modified ordinal scale of 7 points recommended by the World Health Organization.

ResultsWe enrolled 308 patients. Patients randomized to receive therapeutic anticoagulation more frequently had clinical improvement at day 30 when compared to the prophylactic anticoagulation patients [64/75 (85%) versus 51/80 (64%), odds ratio, 3.31; 95% confidence interval, 1.51; 7.26 P=0.003]. Major bleeding was more frequent in the therapeutic anticoagulation group (6.7%) and in the therapeutic anticoagulation plus tocilizumab group (5.0%), compared to the prophylactic anticoagulation group (P=0.02). All-cause mortality at day 30 was significantly lower in therapeutic anticoagulation group (9.3%), when compared to prophylactic anticoagulation group (28.7%), therapeutic anticoagulation plus tocilizumab group (21.5%) and prophylactic anticoagulation plus tocilizumab group (25.7%), P=0.02.

ConclusionsIn this randomized clinical trial involving severe COVID-19 patients, therapeutic anticoagulation resulted in clinical improvement at 30 days. Even if therapeutic anticoagulation increased bleeding, it was associated with a reduced overall mortality. Tocilizumab did not provide additional benefits to heparin in COVID-19 patients.

Trial registrationClinicaltrials.gov NCT04600141. Registered October 22, 2020. https://www.clinicaltrials.gov/study/NCT04600141?term=NCT04600141&amp;rank=1</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.28.23300542">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.28.23300542" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.28.23300542">
        <p class="paperTitle">Addressing the aftermath of the COVID-19 pandemic: A quality improvement collaborative to optimize the use of antibacterials in Argentine Intensive Care Units</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.28.23300542" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.28.23300542" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Jorro-Baron, F.; Loudet, C.; Cornistein, W.; Suarez-Anzorena, I.; Arias-Lopez, P.; Balasini, C.; Cabana, L.; Cunto, E.; Corral, R.; Gibbons, L.; Guglielmino, M.; Izzo, G.; Lescano, M.; Meregalli, C.; Orlandi, C.; Perre, F.; Ratto, M. E.; Rivet, M.; Rodriguez, A. P.; Rodriguez, V. M.; Villegas, P. R.; Vitar, E.; Roberti, J.; Garcia-Elorrio, E.; Rodriguez, V.</p>
        <p class="info">Score: 0.5, Published: 2023-12-29 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.28.23300542' target='https://doi.org/10.1101/2023.12.28.23300542'> 10.1101/2023.12.28.23300542</a></p>
        <p class="abstract">Background: Reducing antimicrobial resistance is a global priority that become even more important after the COVID-19 pandemic. To date there is a scarce volume of evidence from antimicrobial stewardship programs from less resourced settings where this phenomenon is bigger. Our aim was to improve the quality of antibacterials prescription in intensive care units (ICUs) in a middle-income country. Methods: We established a quality improvement collaborative (QIC) model involving nine ICUs over an 11-month period, with a 16-week baseline (BP) and 32-week Intervention (IP) periods. Our co-designed intervention package included audits and feedback on antibacterial use, facility-specific treatment guidelines, antibacterial timeouts, pharmacy-based interventions, and education. The intervention was delivered in two learning sessions with three action periods, along with coaching support and basic quality improvement training. Results: We enrolled 912 patients, with 357 in baseline period (BP) and 555 in implementation period (IP). The latter had higher APACHE II (17 (12, 21) vs. 15 (11, 20); p=0.036) and SOFA scores (6 (4, 9) vs. 5 (3, 8); p=0.006), sepsis (36.1% vs. 31.6%, p&lt;0.001), and septic shock (40.0% vs. 33.8%, p&lt;0.001). Days of antibacterial therapy were similar between groups (IP 1112.2, BP 1133.4, RR 0.98 (0.95-1.02); p=0.2973) and the antibacterial Daily Define Dose was lower in IP group (IP, 1193.0; BP, 1301.0; RR, 0.92 (0.89, 0.95); p=0.0001). The rate of adequate antibacterial adjustment was higher during the IP (62.0% vs. 45.3%, p&lt;0.001). We observed a lower rate of ventilation-associated pneumonia and catheter-associated urinary tract infections related to multidrug-resistant organisms (MDRO) in the IP. There was a noticeable improvement in the Infection Prevention and Control (IPC) Assessment Framework compared to baseline. Conclusion: The implementation of a post pandemic antimicrobial stewardship program in ICUs via a QIC demonstrated success in improving antibacterials utilization, reducing HAIs related to MDRO while also enhancing IPC measures.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        Â· Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
